Low-dose naltrexone (LDN) is a promising new treatment option for various inflammatory and autoimmune conditions. There is a growing body of evidence that the body’s endorphins (naturally occurring opioids) have a critical role in regulating the immune system. Administering LDN between 9 and 11 p.m. blocks opioid receptors for several hours during sleep, setting off a “rebound” effect unique to the lower dose. Naltrexone is effective in 1.5mg to 4.5mg, thus, low doses.
Naltrexone is an opioid antagonist that has been approved for the treatment of opioid addiction at a dose of 50mg. “Low dose” naltrexone refers to the use of a much lower dosage than that used to treat opioid addiction. Naltrexone at this lower dose (up to 4.5mg in most cases) had its first human trial in 2007. Since then, it has shown promise as a treatment for various medical conditions, including multiple sclerosis, Crohn’s disease, fibromyalgia, and more.
LDN is now being studied for a variety of conditions because it is practical as well as safe. There are rarely any side effects reported in studies to date besides some cases of insomnia. The medication is also relatively inexpensive compared to other drugs used to treat these conditions.
Since the commercially available version of naltrexone is too high a dose for treating other conditions besides opioid addiction, LDN must be custom-made at a compounding pharmacy. To find out more about low-dose Naltrexone, call one of our compounding pharmacists at any of our locations.